{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T20:48:43Z","timestamp":1777150123175,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T00:00:00Z","timestamp":1431043200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13277-015-3509-9","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T20:46:10Z","timestamp":1431031570000},"page":"7915-7927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted \u201chsa-miR-2278\u201d as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A"],"prefix":"10.1007","volume":"36","author":[{"given":"Bur\u00e7in Tezcanl\u0131","family":"Kaymaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Selvi","family":"G\u00fcnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Ceyhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildan Bozok","family":"\u00c7etinta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buket","family":"\u00d6zel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melis Kartal","family":"Yand\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sezgi","family":"K\u0131p\u00e7ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fda\u015f","family":"Aktan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysun Adan","family":"G\u00f6kbulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buket Kosova","family":"Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,8]]},"reference":[{"issue":"10","key":"3509_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"key":"3509_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93\u20139.","journal-title":"Cell"},{"key":"3509_CR3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079\u201382.","journal-title":"Science"},{"key":"3509_CR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"3509_CR5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018\u201329.","journal-title":"Lancet Oncol"},{"key":"3509_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Br\u00fcmmendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89\u201399.","journal-title":"Drug Discov Today Technol"},{"issue":"10","key":"3509_CR7","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168\u201371.","journal-title":"Blood"},{"issue":"12","key":"3509_CR8","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1182\/blood-2011-01-332569","volume":"117","author":"AG Turhan","year":"2011","unstructured":"Turhan AG. STAT5 as a CML target: STATinib therapies? Blood. 2011;117(12):3252\u20133.","journal-title":"Blood"},{"issue":"6","key":"3509_CR9","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","volume":"95","author":"C Sillaber","year":"2000","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood. 2000;95(6):2118\u201325.","journal-title":"Blood"},{"issue":"12","key":"3509_CR10","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12):3409\u201320.","journal-title":"Blood"},{"issue":"10","key":"3509_CR11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3109\/10428194.2010.507830","volume":"51","author":"B Kosova","year":"2010","unstructured":"Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, et al. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma. 2010;51(10):1895\u2013901.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3509_CR12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14712598.2015.983070","volume":"15","author":"H Borna","year":"2015","unstructured":"Borna H, Imani S, Iman M, Azimzadeh Jamalkandi S. Therapeutic face of RNAi: in vivo challenges. Expert Opin Biol Ther. 2015;15(2):269\u201385.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"3509_CR13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MOH.0000000000000054","volume":"21","author":"SJ Song","year":"2014","unstructured":"Song SJ, Pandolfi PP. MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Curr Opin Hematol. 2014;21(4):276\u201382.","journal-title":"Curr Opin Hematol"},{"key":"3509_CR14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygeno.2013.06.004","volume":"102","author":"H Wang","year":"2013","unstructured":"Wang H, Hu H, Zhang Q, Yang Y, Li Y, Hu Y, et al. Dynamic transcriptomes of human myeloid leukemia cells. Genomics. 2013;102:250\u20136.","journal-title":"Genomics"},{"issue":"2","key":"3509_CR15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10048-014-0396-y","volume":"15","author":"CM Lill","year":"2014","unstructured":"Lill CM, Schilling M, Ansaloni S, Schr\u00f6der J, Jaedicke M, Luessi F, et al. Assessment of microRNA-related SNP effects in the 3\u2032 untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics. 2014;15(2):129\u201334.","journal-title":"Neurogenetics"},{"issue":"6","key":"3509_CR16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/1756-0500-6-390","volume":"28","author":"C Vaz","year":"2013","unstructured":"Vaz C, Ahmad HM, Bharti R, Pandey P, Kumar L, Kulshreshtha R, et al. Analysis of the microRNA transcriptome and expression of different isomiRs in human peripheral blood mononuclear cells. BMC Res Notes. 2013;28(6):390. doi: 10.1186\/1756-0500-6-390 .","journal-title":"BMC Res Notes"},{"issue":"2","key":"3509_CR17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.gpb.2014.02.001","volume":"12","author":"Q Xiong","year":"2014","unstructured":"Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, et al. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genomics Proteomics Bioinformatics. 2014;12(2):79\u201391.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"12","key":"3509_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115003","volume":"9","author":"S Bhutra","year":"2014","unstructured":"Bhutra S, Lenkala D, LaCroix B, Ye M, Huang RS. Identifying and validating a combined mRNA and MicroRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. PLoS One. 2014;9(12), e115003.","journal-title":"PLoS One"},{"issue":"3","key":"3509_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","volume":"99","author":"S Bibi","year":"2014","unstructured":"Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014;99(3):417\u201329.","journal-title":"Haematologica"},{"issue":"3","key":"3509_CR20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FPC.0b013e328350012b","volume":"22","author":"E Turrini","year":"2012","unstructured":"Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22(3):198\u2013205.","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"3509_CR21","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, et al. Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One. 2013;8(4), e61858.","journal-title":"PLoS One"},{"issue":"2","key":"3509_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-012-1575-2","volume":"92","author":"BT Kaymaz","year":"2013","unstructured":"Kaymaz BT, Selvi N, G\u00fcnd\u00fcz C, Aktan C, Dalm\u0131zrak A, Saydam G, et al. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol. 2013;92(2):151\u201362.","journal-title":"Ann Hematol"},{"issue":"2","key":"3509_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/cr.2008.18","volume":"18","author":"K Zaid Siddiquee Al","year":"2008","unstructured":"Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254\u201367.","journal-title":"Cell Res"},{"key":"3509_CR24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-12-50","volume":"12","author":"U Rozovski","year":"2013","unstructured":"Rozovski U, Calin GA, Setoyama T, D\u2019Abundo L, Harris DM, Li P, et al. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013;12:50.","journal-title":"Mol Cancer"},{"issue":"10","key":"3509_CR25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.leukres.2014.07.004","volume":"38","author":"S Xu","year":"2014","unstructured":"Xu S, Xu Z, Liu B, Sun Q, Yang L, Wang J, et al. LIFR\u03b1-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK\/STAT pathway. Leuk Res. 2014;38(10):1237\u201344.","journal-title":"Leuk Res"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3509-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3509-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3509-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:02:02Z","timestamp":1599001322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3509-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,8]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3509-9","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,8]]}}}